Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐ PD ‐1/ PD‐L1 agents?

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report

(2018) Taiki Hakozaki et al.   BMC CANCER

Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases

(2018) Kohei Fujita et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer

(2018) Scott N. Gettinger et al.   Journal of Thoracic Oncology

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.

(2018) Inderjit Mehmi et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

(2017) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

(2013) C. Robert et al.   CLINICAL CANCER RESEARCH